CTWM
LRMR icon

Cherry Tree Wealth Management’s Larimar Therapeutics LRMR Stock Holding History

Cherry Tree Wealth Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$68.7K Hold
15,264
– – 0.01% 243
2025
Q4 		$58.2K Buy
15,264
+2,000
+15% +$7.78K 0.01% 256
2025
Q3 		$42.8K Buy
13,264
+2,646
+25% +$9.92K 0.01% 270
2025
Q2 		$30.7K Buy
+10,618
New +$24.6K 0.01% 292

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Cherry Tree Wealth Management's LRMR Position: Q1 2026 in Review

Cherry Tree Wealth Management held its Larimar Therapeutics (LRMR) position steady in Q1 2026 at 15,264 shares worth $68.7K. The position accounts for 0.01% of the portfolio, ranked #243.

Cherry Tree Wealth Management first reported a position in LRMR in Q2 2025 and has held it in 4 quarters since. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Cherry Tree Wealth Management held 15,264 shares of Larimar Therapeutics worth $68.7K as of Q1 2026.
  • Cherry Tree Wealth Management left its Larimar Therapeutics share count unchanged in Q1 2026.
  • Larimar Therapeutics made up 0.01% of Cherry Tree Wealth Management's portfolio in Q1 2026, its #243 holding.
  • Cherry Tree Wealth Management first reported a position in Larimar Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Cherry Tree Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.